Brief: Entera Bio Announces Execution Of Key Regulatory Milestones For Eb613, The First Oral Anabolic Drug Proposed For The Treatment Of Osteoporosis Miranda Toledano Assumes CEO Position

Entera Bio

18/07/2022 12:10

July 18 (Reuters) - Entera Bio Ltd  5DT.F :
    * ENTERA BIO ANNOUNCES EXECUTION OF KEY REGULATORY
MILESTONES FOR
EB613, THE FIRST ORAL ANABOLIC DRUG PROPOSED FOR THE TREATMENT
OF OSTEOPOROSIS; MIRANDA TOLEDANO ASSUMES CEO POSITION
    * ENTERA BIO  - U.S. FDA HAS GRANTED ENTERA'S REQUEST FOR A
TYPE C
MEETING BASED ON REVISED PHASE 3 REGISTRATIONAL STUDY FOR LEAD
CLINICAL ASSET, EB613
    * ENTERA BIO LTD - TYPE C MEETING WITH FDA IS EXPECTED IN H2
2022
    * ENTERA BIO LTD - APPOINTED MIRANDA TOLEDANO AS CHIEF
EXECUTIVE
OFFICER (CEO) AS OF JULY 15TH, 2022, SUCCEEDING SPIROS JAMAS

Source text for Eikon:  ID:nGNX5v2gHY 
Further company coverage:  5DT.F 

 ((Reuters.Briefs@thomsonreuters.com;))